Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-08

Prime Medicine (PRME)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,894,187
Allan Reine total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
84.14%
Say-on-pay support, latest vote
Companies that benchmark against PRME
6 companies name PRME as a compensation peer

Each company listed discloses PRME in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PRME in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Allan Reine$606,212$0$0$2,828,798$402,000$0$57,177$3,894,187
Chief Executive Officer
Keith Gottesdiener259,568001,185,80200762,4002,207,770
Former President and Chief Executive Officer
Ann Lee505,37500790,075243,960010,7061,550,116
Chief Technical Officer
Jeremy Duffield268,27100668,60000380,9261,317,797
Former Chief Scientific Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Allan Reine$3,894,187
Keith Gottesdiener2,207,770
Ann Lee1,550,116
Jeremy Duffield1,317,797

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
David P. SchenkeinDirector2026-06-05A75,000$0$0Derivative, Class A CommonForm 4 ↗
Jeffrey D. MarrazzoDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
Robert NelsenDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
Kaye I. Foster-CheekDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
Wendy ChungDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
Thomas CahillDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗
Michael KellyDirector2026-06-05A75,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Allan Reine, M.D.OPTION2025-02-27275,000275,000$471,598
Allan Reine, M.D.OPTION2025-08-01850,000850,000445,801
Keith GottesdienerOPTION2025-02-28500,000
Jeremy DuffieldOPTION2025-02-27275,000
Ann LeeOPTION2025-08-01180,995
Ann LeeOPTION2025-02-27275,000
Allan Reine, M.D.OPTION2025-05-192,000,0002,000,0001,911,400
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Allan Reine, M.D.$0$0$2,828,7990.0%
Keith Gottesdiener00500,0000.0%
Jeremy Duffield00275,0000.0%
Ann Lee00455,9950.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Ann LeeOption56,5614.04
Ann LeeOption217,7092.42
Keith GottesdienerOption155,54412.3
Keith GottesdienerOption395,8342.52
Keith GottesdienerOption54,1678.32
Ann LeeOption98,0394.04
Ann LeeOption17,966,8673.76
Allan ReineOption2,000,0001.34
Allan ReineOption217,7092.42
Ann LeeOption98,0398.49
Allan ReineOption312,5004.04
Ann LeeOption56,56112.3
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is designed to attract, motivate and retain key employees who we believe best represent our values and can make significant contributions towards achieving our purpose of delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases by deploying our Prime Editing technology. Our program's purpose is to incentivize them based on the achievement of key performance goals, and to align their interests with the interests of our stockholders.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantAlpine Rewards
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-08-0171,563,19313,491,02995,83084.14%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-08-0184.14%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jeffrey D. MarrazzoEmployee director · Board Chair$0$0$348,821$95,161$443,982
Michael KellyIndependent · Audit (Chair)65,0000111,61100176,611
Kaye FosterIndependent · Compensation (Chair)60,0000111,89100171,891
Wendy Chung, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance60,0000111,61100171,611
David Schenkein, M.DIndependent · Compensation · Nominating and Corporate Governance (Chair)62,500083,45600145,956
Thomas Cahill, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance60,000083,45600143,456
Robert NelsenIndependent · Compensation52,500083,45600135,956
Allan Reine, M.DEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$360,000
Equity awards (grant-date value)$0
All other compensation$95,161
Total cost of the board$455,161

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Prime Medicine2025Allan Reine$606,212$0$2,828,798$402,000$3,894,187

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Allan ReineDEF 14A2026-04-230001628280-26-026697Section “2025 Summary Compensation Table”. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188
2Section 01, Keith GottesdienerDEF 14A2026-04-230001628280-26-026697Section “2025 Summary Compensation Table”. As printed: 2,207,770. Filing ↗machine: r4 · c42 · span 291171–291180
3Section 01, Ann LeeDEF 14A2026-04-230001628280-26-026697Section “2025 Summary Compensation Table”. As printed: 1,550,116. Filing ↗machine: r6 · c42 · span 297131–297140
4Section 01, Jeremy DuffieldDEF 14A2026-04-230001628280-26-026697Section “2025 Summary Compensation Table”. As printed: 1,317,797. Filing ↗machine: t15 · r8 · c19 · span 301287–301296
5Section 03, Allan Reine, M.D. OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r2 · c10 · span 195599–195606
6Section 03, Allan Reine, M.D. OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r8 · c10 · span 213485–213492
7Section 03, Keith Gottesdiener OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r5 · c4 · span 203458–203465
8Section 03, Jeremy Duffield OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r4 · c4 · span 200486–200493
9Section 03, Ann Lee OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r9 · c4 · span 215340–215347
10Section 03, Ann Lee OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r3 · c4 · span 197504–197511
11Section 03, Allan Reine, M.D. OPTIONDEF 14A2026-04-230001628280-26-026697Section “M.D.” · grants of plan-based awards table. Filing ↗machine: t11 · r6 · c10 · span 207534–207543
12Section 07, pay ratio10-K2026-03-030001628280-26-013569Section “CEO Pay Ratio”. As printed: —. Filing ↗
13Section 08, Jeffrey D. MarrazzoDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 443,982. Filing ↗
14Section 08, Michael KellyDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 176,611. Filing ↗
15Section 08, Kaye FosterDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 171,891. Filing ↗
16Section 08, Wendy Chung, M.D., Ph.DDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 171,611. Filing ↗
17Section 08, David Schenkein, M.DDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 145,956. Filing ↗
18Section 08, Thomas Cahill, M.D., Ph.DDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 143,456. Filing ↗
19Section 08, Robert NelsenDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 135,956. Filing ↗
20Section 08, Allan Reine, M.DDEF 14A2026-04-230001628280-26-026697Section “Director Compensation”. As printed: 0. Filing ↗
21Section 02, David P. Schenkein 2026-06-05Form 42026-06-080001628280-26-041579Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Jeffrey D. Marrazzo 2026-06-05Form 42026-06-080001628280-26-041575Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Robert Nelsen 2026-06-05Form 42026-06-080001628280-26-041572Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Kaye I. Foster-Cheek 2026-06-05Form 42026-06-080001628280-26-041566Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Wendy Chung 2026-06-05Form 42026-06-080001628280-26-041560Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Thomas Cahill 2026-06-05Form 42026-06-080001628280-26-041553Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Michael Kelly 2026-06-05Form 42026-06-080001628280-26-041569Insider equity transaction reported since the proxy statement. Filing ↗
28Section 06, 2025 voteForm 8-K2025-08-050001628280-25-037840Item 5.07 · say-on-pay result. As reported: 84.14% (votes for as printed: 71,563,193). Filing ↗
29Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
30Section 09b board cost (computed)ComputedcomputedCash 360,000 + equity 0 + all other 95,161 = 455,161, summed across the director compensation table rows.machine: formula: Σ = 455,161
31Prime Medicine (subject), Section 10b CEO totalDEF 14A2026-04-230001628280-26-026697CEO total compensation as printed in Prime Medicine's own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188